Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0519-0130 B · 1 trial · 1 indication
Measured in hours\*nanomoles per liter (h\*nmol/L).
| Arm | Type | Description |
|---|---|---|
| Part 1a: NNC0519-0130 C and NNC0519-0130 B | EXPERIMENTAL | Participants will start treatment with formulation NNC0519-0130 C and receive a pre-determined dose escalation regimen of NNC0519-0130 B and NNC0519-0130 C. |
| Part 1b: NNC0519-0130 B and NNC0519-0130 C | EXPERIMENTAL | Participants will start treatment with formulation NNC0519-0130 B and receive a pre-determined dose escalation regimen of NNC0519-0130 B and NNC0519-0130 C. |
| Part 2a: NNC0519-0130 B and NNC0519-0130 C | EXPERIMENTAL | Participants will receive a pre-determined dose escalation regimen of NNC0519-0130 B in run-in period followed by treatment with NNC0519-0130 B then NNC0519-0130 C. |
| Part 2b: NNC0519-0130 C and NNC0519-0130 B | EXPERIMENTAL | Participants will receive a pre-determined dose escalation regimen of NNC0519-0130 B in run-in period followed by treatment with NNC0519-0130 C then NNC0519-0130 B. |
| Name | Type | Description |
|---|---|---|
| NNC0519-0130 B | DRUG | NNC0519-0130 B will be administered subcutaneously. |
| NNC0519-0130 C | DRUG | NNC0519-0130 C will be administered subcutaneously. |
Inclusion Criteria: * Male or female of non-childbearing potential. * Age 18-64 years (both inclusive) at the time of signing the informed consent. * Body Mass Index (BMI) between 27.0 kilogram per square meter (kg/m\^2) and 39.9 kg/m\^2 (both inclusive) at screening. Overweight should be due to ex...
Top 20 of 32 competitors
NNC0519-0130 B is an investigational small molecule being developed for the treatment of obesity. It is currently in Phase 1 clinical development, with one completed trial that enrolled 46 participants with overweight or obesity.
NNC0519-0130 B is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker symbol NVO. The company is conducting clinical research to evaluate this investigational medicine for obesity.
NNC0519-0130 B is in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug remains under clinical investigation for obesity.
NNC0519-0130 B has one completed clinical trial registered as NCT06642571. This Phase 1 study compared how much of the medicine is in the blood of people with overweight or obesity who received two different preparations of the drug. The trial enrolled 46 participants in the United States.
NNC0519-0130 B is a specific preparation of the investigational medicine NNC0519-0130. The clinical trial NCT06642571 was designed to compare two preparations of the medicine, with NNC0519-0130 B being one of the formulations studied in people with overweight or obesity.